Equity Overview
Price & Market Data
Price: $1.46
Daily Change: +$0.05 / 3.42%
Range: $1.39 - $1.49
Market Cap: $52,539,124
Volume: 74,102
Performance Metrics
1 Week: 17.60%
1 Month: -13.02%
3 Months: -31.63%
6 Months: -31.94%
1 Year: -14.53%
YTD: -33.18%
Company Details
Employees: 66
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.